Walleye Capital LLC Has $304,000 Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Walleye Capital LLC decreased its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 75.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,073 shares of the biopharmaceutical company's stock after selling 172,400 shares during the quarter. Walleye Capital LLC owned approximately 0.09% of Sage Therapeutics worth $304,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Thrivent Financial for Lutherans grew its holdings in Sage Therapeutics by 108.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company's stock valued at $405,000 after purchasing an additional 38,876 shares during the last quarter. Amundi bought a new stake in shares of Sage Therapeutics during the 4th quarter worth $166,000. Geode Capital Management LLC grew its stake in Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock valued at $8,975,000 after buying an additional 3,757 shares during the last quarter. SG Americas Securities LLC grew its stake in Sage Therapeutics by 57.7% in the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock valued at $122,000 after buying an additional 8,228 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Sage Therapeutics in the 4th quarter worth $91,000. Institutional investors own 99.22% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group lowered their price target on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, February 12th. Wedbush reaffirmed a "neutral" rating and issued a $6.00 target price on shares of Sage Therapeutics in a report on Wednesday, February 12th. Scotiabank dropped their price target on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research report on Wednesday, February 12th. HC Wainwright reissued a "neutral" rating and issued a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Finally, Piper Sandler dropped their target price on shares of Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating on the stock in a research report on Thursday, January 2nd. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Sage Therapeutics currently has an average rating of "Hold" and a consensus price target of $8.81.

Sage Therapeutics Stock Performance

Shares of SAGE stock traded down $0.31 during trading hours on Wednesday, hitting $7.29. The company had a trading volume of 1,330,418 shares, compared to its average volume of 1,220,039. The firm has a market capitalization of $448.20 million, a price-to-earnings ratio of -1.11 and a beta of 0.48. Sage Therapeutics, Inc. has a 12 month low of $4.62 and a 12 month high of $14.56. The firm's fifty day moving average is $7.54 and its 200 day moving average is $6.77.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The company had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. During the same quarter in the prior year, the company earned ($1.80) earnings per share. The business's revenue was up 78.0% compared to the same quarter last year. On average, sell-side analysts expect that Sage Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.